» Articles » PMID: 37297834

Steroids in Lupus: Enemies or Allies

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Jun 10
PMID 37297834
Authors
Affiliations
Soon will be listed here.
Abstract

Glucocorticoids are the gold standard treatment for reducing immune activation and inflammation in a wide range of inflammatory and systemic autoimmune diseases. Glucocorticoids have potent and fast actions that quickly relieve some symptoms and lower mortality in some life-threatening conditions, but they also have side effects that limit the duration of treatment and the dose used. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the involvement of numerous organs and systems and the production of autoantibodies. Most current treatments include the use of corticosteroids and immunosuppressive medications. Glucocorticoids in SLE have been classically used not only to induce remission or treat an acute situation but also as maintenance therapy. During the last decades, new approaches to managing SLE have emerged, but corticosteroids continue to be part of all therapeutic regimes. There is more and more evidence about the side effects related to the use (or abuse) of steroids and their relationship with the accrual damage. In this manuscript, we try to make a critical review of the published literature about the benefit and side effects/damage that can be attributed to the use of glucocorticoids.

Citing Articles

Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study.

Fang F, Duan H, Ding S Clin Rheumatol. 2025; 44(3):1113-1122.

PMID: 39903405 DOI: 10.1007/s10067-025-07348-5.


Effectiveness of Belimumab for Glucocorticoid Discontinuation in Juvenile-Onset Lupus Nephritis.

Kise T, Uehara M Indian J Nephrol. 2025; 35(1):85-87.

PMID: 39872261 PMC: 11763020. DOI: 10.25259/IJN_444_2024.


Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.

Kaye A, Tassin J, Upshaw W, Patel C, Hawkins A, Burroughs C Cureus. 2025; 16(12):e75062.

PMID: 39759646 PMC: 11698531. DOI: 10.7759/cureus.75062.


Cryptogenic Organizing Pneumonia Is Associated With Increased Mortality Risk in Hospitalizations for Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis.

Uwumiro F, Emmanuel A, Offiah C, Umeani N, Ozigbo A, Idahor C Cureus. 2024; 16(9):e69901.

PMID: 39439634 PMC: 11494845. DOI: 10.7759/cureus.69901.


CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?.

Stojkic I, Harper L, Coss S, Kallash M, Driest K, Lamb M Pediatr Rheumatol Online J. 2024; 22(1):72.

PMID: 39118067 PMC: 11308704. DOI: 10.1186/s12969-024-00990-4.

References
1.
Schacke H, Docke W, Asadullah K . Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002; 96(1):23-43. DOI: 10.1016/s0163-7258(02)00297-8. View

2.
Badsha H, Edwards C . Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum. 2003; 32(6):370-7. DOI: 10.1053/sarh.2002.50003. View

3.
Kyttaris V, Krishnan S, Tsokos G . Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity. 2006; 39(8):705-9. DOI: 10.1080/08916930601061363. View

4.
Mok C, Lau C, Wong R . Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998; 37(8):895-900. DOI: 10.1093/rheumatology/37.8.895. View

5.
Mejia-Vilet J, Ayoub I . The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. Front Med (Lausanne). 2021; 8:622225. PMC: 7921306. DOI: 10.3389/fmed.2021.622225. View